Answers are grounded in this paper and cite their sources.
Background Antimicrobial Resistance (AMR) is a major public health threat in the Eastern Mediterranean Region (EMR), yet surveillance systems often rely on phenotypic and low-resolution technologies. Whole-genome sequencing (WGS) can support infection prevention and control (IPC) through its ability to infer transmission and detect and refute outbreaks. Despite its added value, the economic case in low- and middle-income countries (LMICs) remains rare. We evaluated the cost-effectiveness and affordability of WGS for third-generation cephalosporin-resistant Klebsiella pneumoniae (3GCR Kpn ) within the Tunisian AMR surveillance system (TARSS). Methods We conducted a micro-costing analysis at the National Reference Laboratory of AMR (NRL) (2022), a pragmatic cost-effectiveness analysis from a hospital perspective (2018–2021), and a budget impact analysis across TARSS from hospital, NRL, and system perspectives. WGS was compared with standard care, defined as culture-based identification and antimicrobial susceptibility testing without molecular typing. Outcomes included infections averted, cost per infection averted (CPIA), bed-days avoided, cost per bed-day avoided, WGS net costs, and program affordability. Probabilistic sensitivity analysis (PSA) was the primary uncertainty-informed analysis, and one-way sensitivity (OWSA) was performed. A deterministic base case scenario was calculated using 2018–2021 clusters and prespecified assumptions, including WGS unit cost with 10% overhead, turnaround time, IPC effectiveness, eligible share, and cluster-positive yield. Findings At steady-state NRL throughput of 500 tests per year and full sequencing utilization, WGS cost $232 per test before overheads ($256 with 10% overhead used in the base case), largely driven by consumables (56.8%). In the PSA of 1000 simulations, the median CPIA was $3603 (mean $5225; 95% uncertainty interval $61 to $20,980). Median net cost was $7621 (mean $7711; 95% uncertainty interval $405 to $16,749), and median infections averted were 2.2 (mean 2.7; 95% uncertainty interval 0.5 to 6.8). WGS-informed IPC was cost-effective in 58.8% and 83.3% of simulations at 1- and 2-times Tunisia's GDP per capita, respectively. In the deterministic base case, an estimated $7284 in hospital-side costs under standard of care for infections was averted by WGS-informed IPC. WGS program costs were $11,249, yielding a net cost of $3,965, 3.3 infections averted, 16.5 bed-days, a cost per infection averted of $1,202, and a cost per bed-day avoided of $240. Cost-effectiveness was driven by operational (turnaround time and batch efficiency), transmission (cluster size and cluster-positive yield), and IPC effectiveness. Across all budget impact scenarios, WGS net costs remained <1% of annual budgets across all perspectives. Interpretation WGS-informed IPC was affordable and cost-effective under modelled Tunisian surveillance scenarios, particularly when genomic data are returned rapidly and acted on promptly. Our findings support phased integration of WGS into EMR AMR surveillance systems, prioritizing rapid turnaround time, effective IPC responses, targeted deployment in high-transmission settings, and centralized financing to align incentives across the health system.
No takes yet. Share an insight, caveat, or question.
Itani et al. (2026) studied this question.